BioSpace News Archive

Affimed N.V. announced the presentation at the American Society of Clinical Oncology Annual Meeting of safety and efficacy data from the EGFR mutant NSCLC expansion cohort of its ongoing phase 1/2 study investigating innate cell engager AFM24 as monotherapy.

NewAmsterdam Pharma Company N.V. announced the full results of ROSE2, a Phase 2 clinical trial evaluating obicetrapib, the Company’s oral, low-dose and once-daily cholesteryl ester transfer protein inhibitor, in combination with ezetimibe as an adjunct to high-intensity statin therapy.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, announced positive lead-in data from its ongoing Phase 3 PEAK trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with Gastrointestinal Stromal Tumors.

Gracell Biotechnologies Inc. presented long-term follow-up data from a multicenter study evaluating GC012F, a B-cell maturation antigen and CD19 dual-targeted autologous CAR-T therapeutic candidate, in RRMM during an oral abstract presentation at the 2023 American Society of Clinical Oncology Annual Meeting.

Merck, known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group announced results from the Phase 3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus chemotherapy as first-line treatment for patients with unresectable advanced pleural mesothelioma.

Blueprint Medicines Corporation announced clinical data for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology Annual Meeting.

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.

Replimune Group, Inc. announced updated data from the first 75 patients in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial along with data from the ongoing Phase 1 trial of RP2 combined with nivolumab in patients with uveal melanoma are being presented at the ASCO annual meeting.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI®, a first-in-class BCMAxCD3 bispecific antibody, and talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, showing a high overall response rate among patients with relapsed or refractory multiple myeloma.

Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, presented promising clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023 ASCO annual meeting in Chicago, Illinois.